We had the great pleasure of meeting with Stephanie Nahas (Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA) to discuss the CaMEO results, a web-based survey to characterize self-reported use of preventive medications for migraine and treatment gaps.
The abstract ‘Characterizing preventive treatment gaps in migraine: Results from the CaMEO study’ & ‘Optimal acute treatment is associated with productivity gains in people with migraine: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study’ was presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting 2021, 3-6 June 2021.
- Could you give us a brief overview of the CaMEO study and its objectives? (0:22)
- What did the study reveal about the use of migraine preventative drugs among eligible patients? (1:12)
- What were the reasons for drug discontinuation? (1:50)
- What other treatment gaps were identified? (2:39)
Disclosures: Stephanie Nahas has been on the advisory board for Allergen/AbbVie, Zosano, Nesos Corp (formerly Vorso Corp); speaker for Allergan/AbbVie, Amgen/Novartis, Biohaven, Eli Lilly, Impel, Nesos Corp (formerly Vorso Corp), and has received clinical trial principal investigator support for Teva. Stephanie Nahas is also on the editorial board for Springer (Current Pain and Headache Reports), Wolters-Kluwer (UpToDate), and Neurology Learning Network.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AHS Virtual Annual Scientific Meeting 2021.
Share this Video
Related Videos In Headache Disorders
Raquel Gil-Gouveia, EAN 2022: Highlights in headache and migraine – Treatment advances, strategies for prevention, Anti-CGRP use in migraine, COVID-19
Headache is one of the most common nervous system disorders. In an interview with touchNEUROLOGY, Dr Raquel Gil-Gouveia (Hospital da Luz, Lisbon, Portugal) summarizes the ePoster session she chaired at EAN 2022, ranging from topics such as how COVID-19 has impacted on young people with headaches, the potential of new treatments such as eptinezumab and […]
Stewart Tepper, AAN 2022: Limitations of current treatments for acute migraine
The limitations of the current treatment of acute migraine are said to be patient variability and migraine attack variability. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) discusses the limitations of current treatments for acute migraine and how new treatments overcome these. The abstract entitled ‘Efficacy and Safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the […]
Stewart Tepper, AAN 2022: Phase III MOMENTUM trial results, investigating meloxicam-rizatriptan for the acute treatment of migraine
Meloxicam-Rizatriptan (AXS-07) is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine which combines meloxicam and rizatriptan for the acute treatment of migraine. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) joins us to discuss the phase III MOMENTUM trial aims and design, and the efficacy, safety and tolerability findings of Meloxicam-Rizatriptan for the acute […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!